Ex vivo lung perfusion: A comprehensive review of the development and exploration of future trends

Transplantation

Volumn 96, Issue 6, 2013, Pages 509-518

  Roman, Marius A ^a   Nair, Sukumaran ^a   Tsui, Steven ^a   Dunning, John ^a   Parmar, Jasvir S ^a  

^a PAPWORTH HOSPITAL   (United Kingdom)

Author keywords

Donor optimization; Ex vivo lung perfusion; Lung transplantation; Perfusion

Indexed keywords

ADENOVIRUS VECTOR; ANTIBIOTIC AGENT; ARTIFICIAL LUNG SURFACTANT; CLARITHROMYCIN; CYTOKINE; GLUCOSE; HEPARIN; INTERLEUKIN 10; LACTATE DEHYDROGENASE; LACTIC ACID; METHYLPREDNISOLONE; NITRIC OXIDE; PRESERVATION SOLUTION; PROSTACYCLIN; STEROID;

ACUTE LUNG INJURY; ARTIFICIAL VENTILATION; BRAIN DEATH; EX VIVO LUNG PERFUSION; FILTER; HEART DEATH; HUMAN; HYPERACUTE GRAFT REJECTION; LEUKOCYTE FILTER; LUNG ARTERY PRESSURE; LUNG COMPLIANCE; LUNG EDEMA; LUNG EMBOLISM; LUNG GRAFT REJECTION; LUNG MECHANICS; LUNG PERFUSION; LUNG TRANSPLANTATION; LUNG VENTILATION; NONHUMAN; PRIMARY GRAFT DYSFUNCTION; PRIORITY JOURNAL; REVIEW; TISSUE PRESERVATION;

ANIMALS; FORECASTING; GRAFT SURVIVAL; HISTORY, 20TH CENTURY; HISTORY, 21ST CENTURY; HUMANS; LUNG TRANSPLANTATION; PERFUSION; TISSUE AND ORGAN HARVESTING; TISSUE DONORS; TISSUE SURVIVAL; TREATMENT OUTCOME;

EID: 84884813310     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/TP.0b013e318295eeb7     Document Type: Review

References (97)

1. NHSBT (2012). Organ Donation and TransplantationVActivity Figures for the UK as at 7 September 2012. Available at http://www.organdonation.nhs.uk:8001/ ukt/statistics/downloads/weekly-stats.pdf. Accessed September 17, 2012.
2. Wigfield CH, Love RB. Donation after cardiac death lung transplantation outcomes. Curr Opin Organ Transplant 2011; 16: 462.
3. Cypel M, Yeung J, Keshavjee S. Novel approaches to expanding the lung donor pool: donation after cardiac death and ex-vivo conditioning. Clin Chest Med 2011; 32: 233.
4. Carrel A, Lindbergh C. The culture of whole organs. Science 1935; 81: 621.
5. Steen S, et al. Transplantation of lungs from a non-heart-beating donor. Lancet 2001; 357: 825.
6. Steen S, Ingemansson R, Ericksson L. First human transplantation of a nonacceptable donor lung after reconditioning ex vivo. Ann Thorac Surg 2007; 83: 2194.
7. Cypel M, et al. Technique for prolonged normothermic ex vivo lung perfusion. J Heart Lung Transplant 2008; 27: 1319.
8. Critser JK, et al. Proceedings of the conference on swine in biomedical research. ILAR J 2009; 50: 89.
9. Steen S, et al. Transplantation of lungs from non-heart-beating donors after functional assessment ex vivo. Ann Thorac Surg 2003; 76: 244.
10. Yamada T, et al. Injury of donor lungs from donation after cardiac death in various settings; investigation by RT-PCR and pathology. J Heart Lung Transplant 2010; 29: 1053.
11. Ohsumi A, et al. Protective effect of pre-recovery surfactant inhalation on lungs donated after cardiac death in a canine lung transplantation model. J Heart Lung Transplant 2012; 31: 1136.
12. Chang R, Wright K, Effros R. Role of albumin in prevention of edema in perfused rabbit lungs. J Appl Physiol 1981; 50: 1065.
13. AvsarM, et al. Evaluating a novel albumin free lung perfusion solution in a swine lung transplant model. J Heart Lung Transplant 2012; 31: 1053.
14. Okamoto T, et al. Comparison of extracellular-type-Kyoto solution and Perfadex as a preservation solution in a pig ex vivo lung perfusion model: impact of potassium level. Transplant Proc 2011; 43: 1525.
15. Kraft S, et al. Effect of blood and albumin on pulmonary hypertension and edema in perfused rabbit lungs. J Appl Physiol 1995; 78: 499.
16. Hauge A, Lunde P, Waaler B. Vasoconstriction in isolated blood-perfused rabbit lungs and its inhibition by cresols. Acta Physiol Scand 1966; 66: 226.
17. Pearse D, Sylvester J. Spontaneous injury in isolated sheep lungs: role of resident polymorphonuclear leukocytes. J Appl Physiol 1992; 72: 2475.
18. Medeiros I.L, et al. Histologic and functional evaluation of lungs reconditioned by ex vivo lung perfusion. J Heart Lung Transplant 2012; 31: 305.
19. UK Clinical Research Network: Portfolio Database. DEVELOPUK: A Study of Donor Ex-Vivo Lung Perfusion in United Kingdom Lung Transplantation. ISRCTN 44922411, 2012. Available at http://england.ukcrn. org.uk/StudyDetail.aspx? StudyID=11451. Accessed October 4, 2012.
20. Inci I, et al. Impact of topical cooling solution and prediction of pulmonary graft viability from non-heart-beating donors. J Heart Lung Transplant 2008; 27: 1016.
21. Nakajima D, et al. Hypothermic ex vivo perfusion prevents ischemia reperfusion injury in rat lungs from non-heart-beating donors. J Heart Lung Transplant 2011; 30: S142.
22. Menezes A, et al. Comparison between lungs preserved for 6 and 12 hours using celsior or perfadex in an ex-vivo perfusion rat lung model. Heart Surg Forum 2011; 14: S57.
23. Soares PR, et al. Comparison between Perfadex and locally manufactured low-potassiumdextran solution for pulmonary preservation in an ex vivo isolated lung perfusion model. Transplant Proc 2011; 43: 84.
24. Kerr J, et al. Effect of perfusate glucose concentration on rat lung glycolysis. Am J Physiol 1979; 236: E229.
25. Erasmus ME, et al. Normothermic ex vivo lung perfusion of nonheart- beating donor lungs in pigs: from pretransplant function analysis towards a 6-h machine preservation. Transpl Int 2006; 19: 589.
26. Nakajima D, et al. Reconditioning of lungs donated after circulatory death with normothermic ex vivo lung perfusion. J Heart Lung Transplant 2012; 31: 187.
27. Wipp S, et al. Closed or open circuit during ex-vivo lung perfusion for reconditioning of damaged donor-lungsVwhich shall we use? J Heart Lung Transplant 2010; 29: S79.
28. Valenza F, et al. Beta-adrenergic agonist infusion during extracorporeal lung perfusion: effects on glucose concentration in the perfusion fluid and on lung function. J Heart Lung Transplant 2012; 31: 524.
29. Sasaki M, et al. Influence of pulmonary arterial pressure during flushing on lung preservation. Transplantation 1996; 61: 22.
30. Fu Z, Costello M, Tsukimoto K. High lung volume increases stress failure in pulmonary capillaries. J Appl Physiol 1992; 73: 123.
31. Ohsumi A, et al. A model explaining genotypic and ontogenetic variation of leaf photosynthetic rate in rice (Oryza sativa) based on leaf nitrogen content and stomatal conductance. Ann Bot 2007; 99: 265.
32. Valenza F, et al. The consumption of glucose during ex vivo lung perfusion correlates with lung edema. Transplant Proc 2011; 43: 993.
33. Otani N, et al. Enhanced hippocampal neurodegeneration after traumatic or kainate excitotoxicity in GFAP-null mice. J ClinNeurosci 2006; 13: 934.
34. Koike T, et al. Lactate production during acellular normothermic ex vivo pig and human lung perfusion. J Heart Lung Transplant 2010; 29: S96.
35. Emaminia A, et al. Adenosine A2A agonist improves lung function during ex vivo lung perfusion. Ann Thorac Surg 2011; 92: 1840.
36. Meers CM, et al. Preemptive therapy with steroids but not macrolides improves gas exchange in caustic-injured donor lungs. J Surg Res 2011; 170: e141.
37. Cardoso PF, et al. An experimental rat model of ex vivo lung perfusion for the assessment of lungs after prostacyclin administration: inhaled versus parenteral routes. J Bras Pneumol 2011; 37: 589.
38. Wiebe K, et al. Potential of an injectable polymer to prevent hyperacute rejection of ex vivo perfused porcine lungs. Transplantation 2006; 82: 681.
39. Kurrek MM, et al. Inhaled nitric oxide does not alter endotoxininduced nitric oxide synthase activity during rat lung perfusion. J Appl Physiol 1995; 79: 1088.
40. Lindberg L, et al. Inhalation of nitric oxide after lung transplantation. Ann Thorac Surg 1996; 61: 956.
41. Dong BM, Abano JB, Egan TM. Nitric oxide ventilation of rat lungs from non-heart-beating donors improves posttransplant function. Am J Transplant 2009; 9: 2707.
42. Yeung JC, et al. Ex vivo adenoviral vector gene delivery results in decreased vector-associated inflammation pre- and post-lung transplantation in the pig. Mol Ther 2012; 20: 1204.
43. Cypel M, et al. Functional repair of human donor lungs by IL-10 gene therapy. Sci Translat Med 2009; 1: 4ra9.
44. Fujie K, Shinguh Y, Inamura N. Release of neutrophil elastase and its role in tissue injury in acute inflammation: effect of the elastase inhibitor, FR134043. Eur J Pharmacol 1999; 374: 117.
45. Yoshikawa S, Tsushima K, Koizumi T. Effects of a synthetic protease inhibitor (gabexate mesilate) and a neutrophil elastase inhibitor (sivelestat sodium) on acid-induced lung injury in rats. Eur J Pharmacol 2010; 641: 220.
46. Harada M, et al. Neutrophil elastase inhibitor improves lung function during ex vivo lung perfusion. J Heart Lung Transplant 2012; 31: S221.
47. Khalifé-Hocquemiller T, et al. Ex vivo perfusion worsened lung injuries induced by gastric acid aspiration in rigs. J Heart Lung Transplant 2011; 30: S135.
48. Wipper S, et al. Ex-vivo repair of donor pig-lungs damaged by aspiration. J Heart Lung Transplant 2009; 28: S237.
49. Meers CM, et al. A model of ex vivo perfusion of porcine donor lungs injured by gastric aspiration: a step towards pretransplant reconditioning. J Surg Res 2011; 170: e159.
50. Nath D, et al. Does Perfadex affect outcomes in clinical lung transplantation? J Heart Lung Transplant 2005; 24: 2243.
51. Meers CM, et al. A porcine model to study ex vivo reconditioning of injured donor lungs. J Surg Res 2011; 166: e175.
52. Sahara H, et al. Prevention of hyper-acute pulmonary xenograft dysfunction using GalT-KO swine in an ex-vivo lung perfusion model. Xenotransplantation 2011; 18: 299.
53. Nguyen BN, et al. Absence of Gal epitope prolongs survival of swine lungs in an ex vivo model of hyperacute rejection. Xenotransplantation 2011; 18: 94.
54. Cypel M, et al. 5 years experience with lung donation after cardiac death. J Heart Lung Transplant 2012; 31: 1053.
55. Zamel R, et al. Differential gene regulation between brain and cardiac death donor lungs during ex vivo lung perfusion. J Heart Lung Transplant 2012; 31: S146.
56. CypelM, et al. Ex vivo lung perfusion in clinical lung transplantationVthe "HELP" trial. J Heart Lung Transplant 2010; 29: S88.
57. Wallinder A, et al. Ex-vivo perfusion and transplantation of initially rejected donor lungs. J Heart Lung Transplant 2012; 31: S98.
58. Karamanou DM, et al. The effect of ex-vivo perfusion on the inflammatory profile of the donor lung. J Heart Lung Transplant 2010; 29: S165.
59. Van Raemdonck D. Thoracic organs: current preservation technology and future prospects; part 1: lung. Curr Opin Organ Transplant 2010; 15: 150.
60. Cypel M, et al. Normothermic ex vivo perfusion prevents lung injury compared to extended cold preservation for transplantation. Am J Transplant 2009; 9: 2262.
61. Egan TM, et al. Ex vivo evaluation of human lungs for transplant suitability. Ann Thorac Surg 2006; 81: 1205.
62. Thabut G, et al. Influence of preservation solution on early graft failure in clinical lung transplantation. Am J Respir Crit Care Med 2001; 164: 1204.
63. Rega F, et al. Switch from Euro-Collins to Perfadex for pulmonary graft preservation resulted in superior outcome in transplant recipients. J Heart Lung Transplant 2003; 22: S111.
64. Oto T, et al. Early outcomes comparing Perfadex, Euro-Collins, and Papworth solutions in lung transplantation. Ann Thorac Surg 2006; 82: 1842.
65. Fischer S, et al. Low-potassium dextran preservation solution improves lung function after human lung transplantation. J Thorac Cardiovasc Surg 2001; 121: 594.
66. Muller C, et al. Lung procurement by low-potassium dextran and the effect on preservation injury. Munich Lung Transplant Group. Transplantation 1999; 68: 1139.
67. Cypel M, Keshavjee S. Extracorporeal lung perfusion. Curr Opin Organ Transplant 2011; 16: 469.
68. Cypel M, et al. Normothermic ex vivo lung perfusion in clinical lung transplantation. N Engl J Med 2011; 364: 1431.
69. Kakishita T, et al. Suppression of inflammatory cytokines during ex vivo lung perfusion with an adsorbent membrane. Ann Thorac Surg 2010; 89: 1773.
70. Fildes JE, et al. Ex-vivo lung perfusion reduces graft immunogenicity via the removal of passenger monocytesVa porcine model. Transpl Int 2011; 24: 0934.
71. Takai T, et al. Detection of a quantitative trait locus controlling carbon isotope discrimination and its contribution to stomatal conductance in japonica rice. Theor Appl Genet 2009; 118: 1401.
72. Yamamoto K, et al. Long-term survival after video-assisted thoracic surgery lobectomy for primary lung cancer. Ann Thorac Surg 2010; 89: 353.
73. Fildes JE, et al. Ex-vivo lung perfusion reduces graft immunogenicity via the removal of passenger monocytes-a porcine model. Transpl Int 2011; 24: 225.
74. Fildes JE, et al. Ex-vivo lung perfusion removes donor derived nonclassical monocytes that rapidly differentiate into inflammatory dendritic cells? Transpl Int 2011; 24: 72.
75. Sadaria MR, et al. Cytokine expression profile in human lungs undergoing normothermic ex-vivo lung perfusion. Ann Thorac Surg 2011; 92: 478.
76. Evans CL, Hsu FY, Kosaka T. Utilization of blood sugar and formation of lactic acid by the lungs. J Physiol 1934; 82: 41.
77. Fisher AB, Steinberg H, Bassett D. Energy utilization by the lung. Am J Med 1974; 57: 437.
78. Koike T, et al. Kinetics of lactate metabolism during acellular normothermic ex vivo lung perfusion. J Heart Lung Transplant 2011; 30: 1312.
79. Slama A, et al. Ex vivo LungenperfusionVDer Probelauf vor der Transplantation. Eur Surg 2011; 43: 1682.
80. Pego-Fernandes PM, et al. Ex vivo lung perfusion: early report of Brazilian experience. Transplant Proc 2010; 42: 440.
81. Pego-Fernandes PM, et al. Ex vivo lung evaluation and reconditioning. Rev Bras Cirurg Cardiovasc 2010; 25: 441.
82. Aigner C, et al. Clinical ex vivo lung perfusionVpushing the limits. Am J Transplant 2012; 12: 1839.
83. Zych B, et al. Early outcomes of bilateral sequential single lung transplantation after ex-vivo lung evaluation and reconditioning. J Heart Lung Transplant 2012; 31: 274.
84. George TJ, et al. Physiologic and biochemical profile of clinically rejected lungs on a normothermic ex vivo lung perfusion platform. J Heart Lung Transplant 2012, 31: S105.
85. Yeung JC, et al. Time-course microarray analysis of rejected human donor lungs during 12 hours of acellular normothermic ex vivo lung perfusion. J Heart Lung Transplant 2012; 31: S106.
86. Cypel M, et al. One year survival and functional status of patients from the Human Ex vivo Lung Perfusion (HELP) trial. J Heart Lung Transplant 2011; 30: S8.
87. Cypel M, et al. Experience with the first 50 ex vivo lung perfusions in clinical transplantation. J Thorac Cardiovasc Surg 2012; 144: 1200.
88. Fildes JE, et al. Improved clinical outcome of patients transplanted with reconditioned donor lungs via evlp compared to standard lung transplantation. Transpl Int 2011; 24: 77.
89. Stringer K, et al. Tissue plasminogen activator (tPA) inhibits interleukin- 1 induced acute lung leak. Free Radic Biol Med 1998; 25: 184.
90. Brown CR, et al. Donor lungs with pulmonary embolism evaluated with ex vivo lung perfusion. ASAIO J 2012; 58: 432.
91. Lange C, Togel F, Ittrich H. Administered mesenchymal stem cells enhance recovery from ischemia/reperfusion-induced acute renal failure in rats. Kidney Int 2005; 68: 1613.
92. Kanazawa H, Fujimoto Y, Teratani T. Bone marrow-derived mesenchymal stem cells ameliorate hepatic ischemia reperfusion injury in a rat model. PLoS One 2011; 6: e19195.
93. Lee J, et al. Allogeneic human mesenchymal stem cells for treatment of E. coli endotoxin-induced acute lung injury in the ex vivo perfused human lung. Oric Batk Acad Sci YSA 2009; 106: 16357.
94. Ott HC, Clippinger B, Conrad C. Regeneration and orthotopic transplantation of a bioartificial lung. Nat Med 2010; 16: 927.
95. Song J, Kim S, Liu Z. Enhanced in vivo function of bioartificial lungs in rats. Ann Thorac Surg 2011; 92: 998.
96. Karamanou DM, et al. The effect of ex-vivo perfusion on the microbiological profile of the donor lung. J Heart Lung Transplant 2010; 29: S94.
97. George TJ, et al. Novel nebulized arginase inhibitor increases human lung compliance during normothermic ex vivo lung perfusion. J Heart Lung Transplant 2012; 31: S106.